当前位置： SCI文献检索 > EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY期刊下所有文献 > Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.

Abstract：

PURPOSE:A variety of diagnostic methods are available to validate the performance of population pharmacokinetic models. Internal validation, which applies these methods to the model building dataset and to additional data generated through Monte Carlo simulations, is often sufficient, but external validation, which requires a new dataset, is considered a more rigorous approach, especially if the model is to be used for predictive purposes. Our first objective was to validate a previously published population pharmacokinetic model of darunavir, an HIV protease inhibitor boosted with ritonavir or cobicistat. Our second objective was to use this model to derive optimal sampling strategies that maximize the amount of information collected with as few pharmacokinetic samples as possible. METHODS:A validation dataset comprising 164 sparsely sampled individuals using ritonavir-boosted darunavir was used for validation. Standard plots of predictions and residuals, NPDE, visual predictive check, and bootstrapping were applied to both the validation set and the combined learning/validation set in NONMEM to assess model performance. D-optimal designs for darunavir were then calculated in PopED and further evaluated in NONMEM through simulations. RESULTS:External validation confirmed model robustness and accuracy in most scenarios but also highlighted several limitations. The best one-, two-, and three-point sampling strategies were determined to be pre-dose (0 h); 0 and 4 h; and 1, 4, and 19 h, respectively. A combination of samples at 0, 1, and 4 h was comparable to the optimal three-point strategy. These could be used to reliably estimate individual pharmacokinetic parameters, although with fewer samples, precision decreased and the number of outliers increased significantly. CONCLUSIONS:Optimal sampling strategies derived from this model could be used in clinical practice to enhance therapeutic drug monitoring or to conduct additional pharmacokinetic studies.

journal_name

Eur J Clin Pharmacol

journal_title

European journal of clinical pharmacology

authors

Stillemans G,Belkhir L,Vandercam B,Vincent A,Haufroid V,Elens L

doi

10.1007/s00228-020-03036-2

subject

Has Abstract

pub_date

2020-11-11 00:00:00

eissn

0031-6970

issn

1432-1041

pii

10.1007/s00228-020-03036-2

pub_type

杂志文章

在线工具

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.